COVID

Emerging Infections Program lands national award for COVID response

Vanderbilt’s Emerging Infections Program (EIP) recently received the Toby Merlin Award for Excellence in Emergency Response, presented by the Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry.

From left, Sean Collins, MD, MSc, Wesley Self, MD, MPH, Jessica Collins, program director, Vanderbilt Coordinating Center, and Matt Shotwell, PhD, play key roles in a now-international clinical trial platform that is investigating therapies aimed at reducing complications in patients hospitalized with COVID-19.

VUMC-led COVID-19 clinical trial platform goes international

The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally.

VUMC strongly recommends COVID-19 bivalent booster vaccination as new COVID-19 variants appear in our region

With the development of new variants of the COVID-19 virus across the U.S. and the world, Vanderbilt University Medical Center recommends getting the bivalent booster vaccination.

Reminder: COVID-19 bivalent boosters available through Occupational Health Clinic

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

Bivalent booster vaccine effective in preventing COVID-19 hospitalization in older adults

The new bivalent mRNA COVID-19 booster vaccines that began being used in September are beneficial in preventing COVID-19-associated hospitalization in persons 65 and over.

gloved hand handling sterile surgical tools

Surgical risk persists for patients who’ve had COVID

Vanderbilt researchers report that the trend of decreasing postoperative risk for people who have had COVID persists longer than previously known, for as long as 13 months after COVID.

1 2 3 4 5 40